Targeting FGFR Signaling in Cancer: Bladder and Beyond

Download All
Get up to date on emerging therapeutic strategies to target FGFR in the treatment of patients with cancer with this expert-authored online activity featuring Podcasts, expert commentaries, and downloadable slides.
Alison Birtle, MD, FRCP, FRCR
Ignacio Duran, MD, PhD
Prof. Dr. Arndt Hartmann
Andrea Necchi, MD

Podcasts

Listen to Ignacio Durán, MD, PhD, and Alison Birtle, MD, FRCP, FRCR, discuss the most recent clinical data on targeting FGFR in urothelial cancer and other malignancies.

Alison Birtle, MD, FRCP, FRCR Ignacio Duran, MD, PhD Released: March 23, 2021

Experts, Ignacio Durán, MD, PhD, and Alison Birtle, MD, FRCP, FRCR, discuss the most recent clinical data on targeting FGFR in urothelial cancer and beyond.

Alison Birtle, MD, FRCP, FRCR Ignacio Duran, MD, PhD Released: April 1, 2021

Listen to Ignacio Durán, MD, PhD, and Alison Birtle, MD, FRCP, FRCR, discuss their thoughts on what to know about managing toxicities associated with FGFR inhibitors in the treatment of urothelial cancer and other malignancies.

Alison Birtle, MD, FRCP, FRCR Ignacio Duran, MD, PhD Released: May 4, 2021

Experts, Ignacio Durán, MD, PhD, and Alison Birtle, MD, FRCP, FRCR, discuss their thoughts on what to know about managing toxicities associated with FGFR inhibitors in the treatment of urothelial cancer and other malignancies.

Alison Birtle, MD, FRCP, FRCR Ignacio Duran, MD, PhD Released: May 4, 2021

Downloadable Slidesets

Download this slideset to review the latest data on FGFR signaling in bladder cancer and beyond.

Ignacio Duran, MD, PhD Released: June 14, 2021

Download this short summary slideset of key takeaway points from a text module reviewing the latest data on FGFR signaling in bladder cancer and beyond.

Ignacio Duran, MD, PhD Released: June 14, 2021

ClinicalThought

Expert faculty discusses FGFR signaling, possible consequences of FGFR alterations in tumor development, and current FGFR testing methods and prognostic value.

Prof. Dr. Arndt Hartmann Released: April 9, 2021

An expert’s thoughts on what healthcare professionals need to know about FGFR alterations and targeted therapies for bladder cancer.

Andrea Necchi, MD Released: April 30, 2021

Module

Gain expert insights on targeting FGFR signaling in bladder cancer and other malignancies.

Ignacio Duran, MD, PhD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: June 14, 2021 Expired: No longer available for credit
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Janssen Pharmaceutica NV

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings